|Date Announced:||December 04, 2018|
|Date Closed:||December 07, 2018|
|Client Name:||Emerald Health Therapeutics, Inc.|
We acted for Emerald Health Therapeutics, Inc. (the "Company") in connection with its prospectus sale to a single Canadian institutional accredited investor (the "Investor") of 4,000,000 common shares (each, a "Common Share") of the Company at a price per Common Share of $2.70, for gross proceeds of $10.8 million.
The Investor was grated the option to acquire up to a maximum of 1,555,555 additional Common Shares at a price per Common Share of $2.70 for a period of 10 business days from the closing date. Such option was not, however, exercised.
The Common Shares were offered by way of a shelf prospectus supplement filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101 – Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions.